Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
IPX066 achieves therapeutic LD plasma concentration by 1 h and maintains them for 4–5 h before declining Open-label conversion of PD patients on CR CD-LD ± IR to IPX066. Treatment was between 6 and 12 m UPDRS Part III scores significantly improved, favoring IPX066 at 4 and 5 h post-dose (p < .05 and p < .01) 65.6% of patients preferred IPX066; 12.5% preferred their previous therapy; 21.9% had no preference PD patients on CR CD-LD ± IR were switched safely to IPX066. By 6-m ≥ 68.8% experienced meaningful clinical benefit